OBJECTIVE Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. METHOD In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S). RESULTS After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=-1.4, 95% CI=-2.5, -0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=-0.5, 95% CI=-0.8, -0.1) and as not severely unwell (CGI-S: treatment difference=-0.3, 95% CI=-0.5, 0.0) by the treating clinician. Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance (BACS: treatment difference=1.31, 95% CI=-0.10, 2.72) and in overall functioning (GAF: treatment difference=3.0, 95% CI=-0.4, 6.4). CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups. CONCLUSIONS These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.

中文翻译：

---

大麻二酚 (CBD) 作为精神分裂症的辅助治疗：一项多中心随机对照试验。

目的 对动物和人类的研究表明，大麻二酚 (CBD) 具有抗精神病特性。作者评估了 CBD 在精神分裂症患者中的安全性和有效性。方法 在一项探索性双盲平行组试验中，精神分裂症患者以 1:1 的比例随机接受 CBD（1000 mg/天；N=43）或安慰剂（N=45）以​​及他们现有的抗精神病药物。参与者在治疗前后使用阳性和阴性综合征量表 (PANSS)、精神分裂症认知简要评估 (BACS)、功能性全球评估量表 (GAF) 以及临床总体印象的改善和严重程度量表进行评估规模（CGI-I 和 CGI​​-S）。结果 治疗 6 周后，与安慰剂组相比，CBD 组的阳性精神病症状水平较低（PANSS：治疗差异=-1.4，95% CI=-2.5，-0.2），更有可能被评为改善（CGI-I：治疗差异=-0.5， 95% CI=-0.8, -0.1) 并且由治疗临床医生判断为没有严重不适 (CGI-S: 治疗差异=-0.3, 95% CI=-0.5, 0.0)。接受 CBD 的患者在认知能力（BACS：治疗差异=1.31, 95% CI=-0.10, 2.72）和整体功能（GAF：治疗差异=3.0, 95% CI= -0.4, 6.4)。CBD 耐受性良好，CBD 组和安慰剂组的不良事件发生率相似。结论 这些研究结果表明 CBD 对精神分裂症患者具有有益作用。作为CBD'